Details for Patent: 9,889,138

Which drugs does patent 9,889,138 protect, and when does it expire?

Patent 9,889,138 protects TAZVERIK and is included in one NDA.

This patent has twenty-three patent family members in twelve countries.

Summary for Patent: 9,889,138

Title:	Method for treating cancer
Abstract:	The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.
Inventor(s):	Heike Keilhack
Assignee:	Epizyme Inc
Application Number:	US15/211,792
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,889,138

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		DISCN	Yes	No						METHOD OF TREATING EPITHELIOID SARCOMA
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		DISCN	Yes	No						METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Epizyme Inc	TAZVERIK	tazemetostat hydrobromide	TABLET;ORAL	211723-001	Jan 23, 2020		DISCN	Yes	No						METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

International Family Members for US Patent 9,889,138

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015331729
Australia	2021200995
Australia	2022221580